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Design: Focus	 groups	were	 conducted	with	 people	 living	with	memory	 problems	








Discussion and conclusions: The	key	domains	identified	are	being	used	to	inform	the	
next	stage	of	the	ePSOM	programme	which	is	to	develop	a	survey	to	be	distributed	
nationally	in	the	UK	to	explore	these	issues	further.
K E Y W O R D S
Alzheimer’s	disease	clinical	trials,	disease	prevention,	focus	groups,	Patient	Preferences,	
Patient‐Reported	Outcome	Measures
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1  | BACKGROUND
Within	health	and	social	care,	a	central	tenet	of	national	policy	is	to	
ensure	 services	work	 to	 support	 people	 to	 achieve	 their	 personal	
outcomes,	defined	as	 the	 things	 important	 to	people	 in	 their	 lives	
and that help them to achieve well‐being.1	A	similar	 focus	on	per‐
sonal	outcomes	has	been	developing	in	parallel	within	clinical	med‐













important	 to	 the	 person	 themselves.	Work	 is	 underway	 to	 estab‐





The	 rising	 incidence	 of	 dementia	 and	 associated	 challenges	
in	 health	 and	 social	 care	 provision	 is	 linked	 to	 population	 ageing.	
However,	developments	 in	 imaging	and	molecular	medicine	are	be‐
ginning	 to	 redefine	 our	 understanding	 of	 the	 natural	 development	












An	 emerging	 view	 is	 that	 optimal	 disease	 modification	 using	
pharmaceuticals	will	 best	 be	 achieved	 at	 earlier	 stages	of	 the	dis‐




window	 of	 intervention	 opportunity	 before	 overt	 and	 irreversible	
cognitive	change	occurs.	This	has	led	to	a	paradigm	shift	where	AD	




The	 first	 challenge	 in	 drug	 development	 in	AD	 is	 that	 there	 is	
no	consensus	on	the	optimal	approach	for	outcome	assessment	 in	













considered.14,15	 A	 survey	 which	 included	 people	 with	 no	 cognitive	
impairment,	people	with	mild	cognitive	 impairment	and	people	with	



























1.1 | Involving people who experience decline and 
those at risk of developing dementia
As	a	first	step,	it	is	good	practice	to	involve	patients	in	PROM	de‐
velopment.19	The	FDA	recommends	that	patients,	as	well	as	health	
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professionals	and	family	carers,	should	be	 involved	in	 instrument	
item	generation	using	focus	groups	or	interviews.20	This	is	to	en‐
sure	 the	 focus	 is	on	 issues	of	greatest	 importance	and	relevance	
to	patients	and	to	ensure	completeness	and	understanding	of	the	
items	to	be	 included.	The	focus	towards	the	earlier	stages	of	AD	





also	 important	 for	 identifying	 subtle	 changes	 which	 new	 treat‐






treatments	 and	 how	 they	 make	 trade‐offs	 between	 benefit	 and	
potential	harm.	The	experiences	of	health	professionals	who	have	
treatment	 discussions	 with	 patients	 experiencing	memory	 prob‐
lems	are	also	relevant.
2  | AIMS
1.	 To	 explore	 what	 outcomes	 matter	 to	 people	 in	 clinical	 trials	
to	 slow	 or	 prevent	 dementia














The	 advantages	 of	 using	 focus	 groups	with	 people	with	mem‐
ory	problems	are	that	there	is	 less	pressure	to	contribute	com‐
pared	 to	 individual	 interviews,	 people	 can	 feel	 supported	 and	
empowered	 when	 they	 are	 with	 people	 who	 share	 similar	 ex‐
periences,	 and	 sharing	 experiences	may	 trigger	 recall.21 There 
were	two	focus	groups	with	healthy	volunteers	and	three	focus	
groups	with	people	with	memory	problems.	The	number	of	focus	
groups	was	 based	 on	 the	 resources	 available	 and	 deemed	 suf‐
ficient	 given	 that	 in	 later	 groups,	no	new	 themes	were	arising,	
thus	 achieving	 data	 saturation.23	 Telephone	 interviews	 were	
conducted	with	health	and	social	care	professionals.	Telephone	
interviews	 are	 a	 valid	 and	 recognized	 method	 for	 collecting	
qualitative	data	with	 the	advantage	of	being	 low	cost	 in	 terms	




People	 aged	 over	 50	years	 who	 self‐identified	 with	 subjective	
cognitive	 impairment,	 self‐identified	 or	 had	 been	 diagnosed	with	





Society	 and	 Alzheimer's	 Research	 UK	 which	 allows	 people	 to	
register	 their	 interest	 in	 participating	 in	 dementia	 research	
and	 be	 matched	 to	 suitable	 studies,	 with	 consent	 to	 be	 ap‐
proached	 directly	 by	 researchers.	 Nine	 people	 with	 memory	
problems,	 nine	 healthy	 volunteers	 plus	 another	 through	 word	
of	 mouth	 were	 recruited	 through	 this	 route.
2.	 The	 Centre	 for	 Dementia	 Prevention	 at	 the	 University	 of	
Edinburgh	is	a	study	partner	and	holds	a	database	of	people	who	
have	consented	to	be	approached	by	researchers	about	suitable	





3.	 The	 study	 was	 advertised	 through	 Alzheimer	 Scotland's	 social	
media	networks,	and	those	interested	were	asked	to	contact	re‐
searchers	 directly.	 Three	 people	 with	 memory	 problems	 were	
recruited	through	this	route.












Focus	 groups	 lasted	 1.5‐2	hours	 and	 followed	 the	Core	 Principles	
for	 Involving	People	with	Dementia	 in	Research	24.	Relevant	areas	
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explored	 in	 interviews	 are	 shown	 in	 Table	 1.	 Two	 researchers	 fa‐
cilitated	the	groups	(JW,	SS).	Discussions	were	audio	recorded	with	
consent	and	fully	transcribed.	Detailed	notes	were	taken	from	tel‐
ephone	 interviews.	All	 names	were	 removed	 and	each	participant	






A	 further	 reading	 of	 the	 transcripts	 was	 undertaken	 by	 JW	 (an	
experienced	 qualitative	 researcher),	 and	 the	 inductively	 derived	
codes	were	 grouped	 into	 two	overarching	 themes	with	 five	 and	
two	subthemes,	respectively.	Repeated	reading	of	the	transcripts	
was	undertaken	by	JW	to	ensure	the	thematic	framework	devel‐
oped	 was	 comprehensive	 and	 covered	 the	 three	 perspectives.	
Data	were	managed	using	NIVIVO	software.	Key	themes	and	data	
coded	to	these	themes	were	presented	to	the	full	study	team	for	















The	 findings	 are	 organized	 into	 two	 overarching	 themes	 which	
reflect	what	matters	in	developing	treatments	to	prevent	Alzheimer's	
disease:	what	matters	 in	everyday	 life;	what	matters	 in	making	deci‐
sions	about	treatments.	Findings	across	the	three	participating	groups,	
namely	people	with	memory	problems,	healthy	volunteers	and	health	
and	 social	 care	professionals,	 are	 explored	within	 the	narrative	with	
direct	quotes	from	people	with	memory	problems	and	healthy	volun‐
teers	and	detailed	notes	from	professionals	presented	in	Tables	4‐10.
TA B L E  1  Relevant	areas	explored	in	interviews	across	groups
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3.5.1 | What matters in everyday life
There	were	five	key	 interdependent	subthemes	which	emerged	as	




fidently	 doing	 taken‐for‐granted	 everyday	 things	 at	 home	 (Table	4	
quote	1),	such	as	doing	laundry	(Table	4	Quote	2).	Not	being	able	to	
care	for	family	through,	for	example	cooking,	led	to	strong	emotions	




















































TA B L E  1   (Continued)




Everyday	 Functioning,	 for	 people	with	memory	 problems,	 it	went	





















tity	was	not	raised	 in	the	context	of	what	matters	 in	everyday	 life	
but	is	discussed	further	below	in	the	context	of	the	significance	of	
the	risk	of	dementia.
Relationships and Social Connections
Health	 and	 social	 care	 professionals	 identified	 how	 people	 can	 be‐






























£0‐£24 000 10 6
£24	001‐£60	000 9 3
More	than	£60	000 0 1
Do not know 2 0
TA B L E  2  Participant	demographics:	
people	experiencing	memory	problems	
and	healthy	volunteers
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At	 the	beginning	of	 focus	groups	with	healthy	volunteers,	 they	
were	asked	if	they	had	any	personal	experience	of	dementia,	either	















TA B L E  4  Everyday	Functioning	from	the	perspective	of	people	with	memory	problems,	healthy	volunteers	and	health	and	social	care	
professionals	(Each	quote	labelled	with	quote	number	plus	unique	identifier	code	of	each	participant)



















































People with memory problems Healthy Volunteers



















































kidding yourself on” (013):








Health	 and	 social	 care	 professionals	 did	 not	 prioritize	 im‐
proved	memory	as	an	indicator	of	effectiveness	of	treatment	as	
highly	 as	 others.	While	 they	 recognized	memory	 as	 important,	
in	 their	 experience,	 they	 had	 seen	 people	 benefit	 from	 treat‐
ments	 and	 support	 through	 regaining	 confidence	 in	 Everyday	
Functioning,	 even	 if	 their	 scores	 on	 memory	 tests	 did	 not	 im‐
prove	(Table	8	Quote	5).
Health	 and	 social	 care	 professionals	were	more	 likely	 to	men‐
tion,	without	prompting,	symptoms	of	dementia	other	than	memory	
People with memory problems Healthy volunteers































































they were working and can 
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problems,	 for	example	 “Sleep disturbance. A good outcome for them 
might be a better night's sleep” HSP	002.





The significance of reducing the risk of dementia with drugs
This	 subtheme	 came	 from	 data	 collected	 from	 healthy	 volunteers	
only.	It	was	not	explored	with	those	who	were	in	the	memory	prob‐

















Balancing risk against benefits
There	were	 two	 categories	 of	 risk	 considered	 in	 relation	 to	 the	
decision‐making	about	preventative	treatments:	the	risk	of	devel‐
oping	dementia	and	the	risk	of	side‐effects	of	drugs.	In	the	current	
context	 of	 no	 cure	 for	 dementia,	 knowing	 your	 risk	 of	 develop‐
ing	dementia	was	 seen	as	unhelpful	 by	 some	healthy	volunteers	
(Table	10	Quote	1).
TA B L E  7  Enjoying	life	from	the	perspective	of	people	with	memory	problems,	healthy	volunteers	and	health	and	social	care	professionals	
(Each	quote	labelled	with	quote	number	plus	unique	identifier	code	of	each	participant)
People with memory problems Healthy volunteers






























TA B L E  8  Alleviating	Symptoms	from	the	perspective	of	people	with	memory	problems,	healthy	volunteers	and	health	and	social	care	
professionals	(Each	quote	labelled	with	quote	number	plus	unique	identifier	code	of	each	participant)
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Some	healthy	volunteers	did	not	initially	hesitate	to	consider	tak‐
ing	drugs	 to	prevent	dementia	when	asked	early	 in	 the	discussion	
about	 taking	 them.	However,	 they	 sounded	 a	more	 cautious	 note	
later	in	the	discussion	once	they	had	considered	the	various	trade‐









ied	 across	 all	 participants	 and	 the	 discussion	 in	 both	 healthy	 vol‐





aspects	 that	 matter	 in	 everyday	 life	 discussed	 earlier	 (Table	 10	 
Quote	6).
Healthy	volunteers	were	overall	more	able	 to	engage	 in	 think‐
ing	 about	 how	 to	 trade‐off	 the	 probability	 of	 benefitting	 from	 a	
drug	treatment	against	the	probability	of	experiencing	a	side‐effect	
(Table	10	Quote	7).









In	 terms	of	 the	 trade‐off	between	benefits	 and	harms	of	drug	
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4  | DISCUSSION
The	paradigm	 shift	 towards	prevention	of	AD	where	 clinical	 trials	
now	 seek	 to	 enrol	 people	with	mild	 cognitive	 impairment	 and	 no	
cognitive	impairment	has	raised	new	methodological	and	analytical	
challenges	 which	 require	 understanding.	 This	 paper	 presents	 re‐
search	that	addresses	two	of	these	challenges:	understanding	what	
outcomes	matters	 to	 people	 taking	 part	 in	 trials	 for	 preventative	
drugs,	 and	 understanding	 how	 people	 think	 about	 making	 trade‐




disease.	 This	 study	 explored	 these	 issues	 from	 the	perspective	of	
people	with	subjective	cognitive	impairment,	mild	cognitive	impair‐
ment,	mild	Alzheimer's	disease,	healthy	volunteers	and	health	and	





people	 with	 experience	 of	 informal	 caring	 which	 counteracts	 the	
limitations	to	some	degree.	The	blurring	of	the	lines	and	overlap	be‐
tween	people	in	the	healthy	volunteer	groups	and	the	memory	prob‐








TA B L E  1 0  Balancing	Risks	against	Benefits	from	the	perspective	of	people	with	memory	problems,	healthy	volunteers	and	health	and	
social	care	professionals	(Each	quote	labelled	with	quote	number	plus	unique	identifier	code	of	each	participant)
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The	findings	highlight	that	what	matters	 in	developing	new	treat‐
ments	to	prevent	Alzheimer's	disease	mirrors	what	matters	in	everyday	
life	 and	needs	 to	attend	 to:	Everyday	Functioning,	 Sense	of	 Identity,	





of	 the	 ePSOM	 development	 programme.	 Some	 problems,	 such	 as	













It	 was	 recognized	 that	 how	 people	 define	 “Enjoying	 Life”	 is	
individual,	 and	 therefore,	 measuring	 the	 effectiveness	 of	 new	
treatments	on	 their	ability	 to	help	people	continue	to	enjoy	 life	
needs	 to	be	personalized	 to	 some	extent.	This	personalized	ap‐
proach	is	integral	to	the	development	of	the	ePSOM	app.	It	must	
also	be	noted	 that	measures	of	effectiveness	 in	clinical	 trials	 to	
slow	 or	 prevent	 dementia	 take	 place	 in	 the	 context	 of	 broader	
health	issues	and	the	physical	effects	of	ageing	which	can	impact	
on	the	ability	to	enjoy	life.	This	further	adds	to	the	complexity	of	






this	 was	 the	 view	 that	 we	 are	 defined	 by	 our	minds:	 dementia	
was	 seen	 as	 taking	 away	 the	mind	 and,	 by	 implication,	 the	per‐
son.	Being	defined	by	 “my	mind”	 reflects	 contemporary	 culture	
which	holds	rationality,	cognition	and	memory	as	core	aspects	of	
the	self.28	When	dementia	 leads	 to	 the	 loss	of	 these	aspects	of	
selfhood,	the	person	is	diminished	in	the	eyes	of	society	and,	as	
shown	here,	in	their	own	eyes.	Insights	from	some	of	the	people	
with	memory	 problems	 show	 how	 they	 felt	 like	 “I'm	 not	 there”	
when	family	members	denied	them	the	opportunity	to	continue	
with	 everyday	 tasks	 such	 as	 doing	 the	 ironing.	 Milne	 et	 al	 (p.	
982)27	describe	this	as	being	“corporeally	present	but	cognitively	
absent”	and	 it	underlines	how	overlooking	embodied	aspects	of	
selfhood29	 leads	 to	 exclusion	 and	 suffering	 of	 people	 with	 de‐
mentia	 as	 they	 become	 seen	 as	 non‐persons.	 This	 may	 shape	
views	 of	 risk	 decisions	 about	 developing	 dementia	 in	 powerful	
ways.	Hearing	the	direct	experience	of	those	already	experienc‐
ing	this	is	important	as	it	highlights	that	some	of	the	solutions	to	
















and	 change	 people's	 assessment	 of	 the	 harmful	 consequences	 of	







This	 study	 gives	 insights	 into	 the	 aspects	 of	 everyday	 life	
which	are	important	to	consider	when	measuring	the	effective‐
ness	 of	 new	 treatment	 to	 slow	 and	 prevent	 dementia,	 namely	
Everyday	 Functioning,	 Sense	 of	 Identity,	 Relationships	 and	
Social	 Connections,	 Enjoying	 Life	 and	 Alleviating	 Symptoms.	
Also,	it	provides	insights	into	how	people	assess	the	significance	
of	reducing	the	risk	of	dementia	with	drugs,	and	how	they	weigh	
up	 benefits	 and	 potential	 harms	 of	 drugs.	 The	 perspectives	 of	
people	experiencing	memory	problems,	healthy	volunteers	and	
health	 and	 social	 care	 professionals	 are	 compared	 and	 con‐
trasted.	In	the	ePSOM	programme,	the	focus	groups	were	a	vital	



















analysis	 and	 interpretation	of	data.	 JW	drafted	 the	article.	All	 au‐
thors	involved	in	revising	and	final	approval	of	the	article.
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